share_log

BioAffinity Technologies, Subsidiary Oncoselect Therapeutics, Has Been Granted U.S. Patent Number 11,590,233 Titled "Porphyrin Compounds And Compositions Useful For Treating Cancer"

Benzinga ·  Mar 1, 2023 00:35
BioAffinity Technologies, Subsidiary Oncoselect Therapeutics, Has Been Granted U.S. Patent Number 11,590,233 Titled "Porphyrin Compounds And Compositions Useful For Treating Cancer"
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment